Zacks Research Has Bullish Forecast for Novavax Q1 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at Zacks Research increased their Q1 2027 earnings estimates for Novavax in a research note issued on Tuesday, July 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($0.13) per share for the quarter, up from their previous estimate of ($0.15). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Novavax’s current full-year earnings is ($0.19) per share. Zacks Research also issued estimates for Novavax’s Q2 2027 earnings at ($0.05) EPS and FY2027 earnings at $0.07 EPS.

Several other research analysts have also recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a report on Thursday, June 11th. Jefferies Financial Group reiterated a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. Wall Street Zen raised Novavax from a “sell” rating to a “hold” rating in a research report on Sunday, May 31st. B. Riley Financial restated a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Finally, TD Cowen lifted their price objective on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $13.00.

Novavax Stock Down 1.2%

NASDAQ NVAX opened at $9.35 on Thursday. The firm has a 50-day moving average price of $9.31 and a two-hundred day moving average price of $8.88. Novavax has a 12-month low of $6.20 and a 12-month high of $11.97. The company has a market capitalization of $1.54 billion, a P/E ratio of -16.12 and a beta of 2.43.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.19. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The business had revenue of $118.90 million for the quarter, compared to analyst estimates of $79.81 million. During the same period last year, the firm earned $2.93 earnings per share. Novavax’s revenue for the quarter was down 79.0% compared to the same quarter last year.

Hedge Funds Weigh In On Novavax

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new stake in shares of Novavax during the 4th quarter worth approximately $33,000. Quarry LP acquired a new position in Novavax during the third quarter valued at approximately $33,000. Duncker Streett & Co. Inc. raised its position in Novavax by 917.3% during the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 3,825 shares in the last quarter. KBC Group NV raised its position in Novavax by 34.9% during the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,229 shares in the last quarter. Finally, State of Wyoming bought a new stake in Novavax during the second quarter worth $52,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Zacks Research upgraded Novavax from Hold to Strong-Buy, which may have helped sentiment around the shares. Zacks upgrade article
• Positive Sentiment: The same research team raised multiple earnings estimates for Novavax, including Q3 2027, Q4 2027, Q1 2028, Q2 2028, and FY2028, signaling improved expectations for future profitability.
• Positive Sentiment: Zacks maintained a Strong-Buy rating and now sees FY2028 EPS at $1.41, up from $1.29, reinforcing a more bullish long-term outlook.
• Neutral Sentiment: Novavax was also listed as a trending stock on Zacks, suggesting rising investor attention but not necessarily a direct fundamental catalyst.
• Negative Sentiment: Despite the upbeat analyst revisions, NVAX traded lower than the general market in the most recent session, indicating investors were still cautious and the stock remained volatile.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.